These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 35169512)
1. Are female bipolar patients of reproductive age aware of the teratogenic risk of sodium valproate? A qualitative study. Sibanyoni AU; Joubert M; Naidu K S Afr J Psychiatr; 2022; 28():1719. PubMed ID: 35169512 [TBL] [Abstract][Full Text] [Related]
2. Measures to Mitigate Sodium Valproate Use in Pregnant Women With Epilepsy. Ranjith S; Joshi A Cureus; 2022 Oct; 14(10):e30144. PubMed ID: 36381886 [TBL] [Abstract][Full Text] [Related]
3. The valproate prescription pattern for female mental healthcare users of reproductive age. Gasa PS; Tomita A; Juby V; Paruk S S Afr J Psychiatr; 2024; 30():2158. PubMed ID: 38628904 [TBL] [Abstract][Full Text] [Related]
4. Patterns in Psychiatrists' Prescription of Valproate for Female Patients of Childbearing Age With Bipolar Disorder in Japan: A Questionnaire Survey. Tachibana M; Hashimoto T; Tanaka M; Watanabe H; Sato Y; Takeuchi T; Terao T; Kimura S; Koyama A; Ebisawa S; Shizu Y; Nagase T; Hirakawa J; Hatta K; Nakazato M; Iyo M Front Psychiatry; 2020; 11():250. PubMed ID: 32351410 [TBL] [Abstract][Full Text] [Related]
5. Teratogenic medications and concurrent contraceptive use in women of childbearing ability with epilepsy. Bhakta J; Bainbridge J; Borgelt L Epilepsy Behav; 2015 Nov; 52(Pt A):212-7. PubMed ID: 26460786 [TBL] [Abstract][Full Text] [Related]
6. Brief intervention reduces prescription of sodium valproate in women of childbearing age. Goldspink R; Pumipi T; Menkes DB Australas Psychiatry; 2023 Aug; 31(4):524-527. PubMed ID: 37035997 [TBL] [Abstract][Full Text] [Related]
7. Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach? Macfarlane A; Greenhalgh T BMC Pregnancy Childbirth; 2018 Jun; 18(1):200. PubMed ID: 29859057 [TBL] [Abstract][Full Text] [Related]
8. Sodium valproate prescription to women of childbearing age in a New Zealand inpatient psychiatric unit. Goldspink R; Pumipi T; Dey S; Menkes DB Australas Psychiatry; 2020 Oct; 28(5):555-558. PubMed ID: 32586113 [TBL] [Abstract][Full Text] [Related]
9. The emerging story of Sodium Valproate in British newspapers- A qualitative analysis of newspaper reporting. Siriwardena S; McAllister N; Islam S; Craig J; Kinney M Seizure; 2022 Oct; 101():127-133. PubMed ID: 35973301 [TBL] [Abstract][Full Text] [Related]
10. A UK clinical audit addressing the quality of prescribing of sodium valproate for bipolar disorder in women of childbearing age. Paton C; Cookson J; Ferrier IN; Bhatti S; Fagan E; Barnes TRE BMJ Open; 2018 Apr; 8(4):e020450. PubMed ID: 29654033 [TBL] [Abstract][Full Text] [Related]
12. Prescription of Sodium Valproate as a Mood Stabiliser in Pregnancy. Womersley K Psychiatr Danub; 2017 Sep; 29(Suppl 3):679-684. PubMed ID: 28953852 [TBL] [Abstract][Full Text] [Related]
13. The Awareness and Adherence of the Valproate Pregnancy Prevention Program: A Questionnaire Survey among Healthcare Professionals, Pharmacists, and Patients in Denmark. Oliveri NMB; Hansen JM; Almarsdóttir AB; Jacobsen R Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767582 [TBL] [Abstract][Full Text] [Related]
14. Valproate prescription to women of childbearing age in English primary care: repeated cross-sectional analyses and retrospective cohort study. Gaudio M; Konstantara E; Joy M; van Vlymen J; de Lusignan S BMC Pregnancy Childbirth; 2022 Jan; 22(1):73. PubMed ID: 35086478 [TBL] [Abstract][Full Text] [Related]
15. Teratogenic risk and contraceptive counselling in psychiatric practice: analysis of anticonvulsant therapy. Langan J; Perry A; Oto M BMC Psychiatry; 2013 Sep; 13():234. PubMed ID: 24066860 [TBL] [Abstract][Full Text] [Related]
16. Sodium valproate in psychiatric practice: time for a change in perception. Owens DC Br J Psychiatry; 2019 Sep; 215(3):516-518. PubMed ID: 31190658 [TBL] [Abstract][Full Text] [Related]
17. The impact and challenges of the 2018 MHRA statement on the use of sodium valproate in women of childbearing age during the first year of implementation, in a UK epilepsy centre. Davies P; Reuber M; Grunewald R; Howell S; Dickson J; Dennis G; Shanmugarajah P; Tsironis T; Brockington A Seizure; 2020 Jul; 79():8-13. PubMed ID: 32380376 [TBL] [Abstract][Full Text] [Related]
18. Is the Medicines and Healthcare products Regulator Agency (MHRA) guidance on sodium valproate acceptable to women of childbearing age? Morrison I; Cork H; Smith P; Campbell C; Megan McTiernan M; White K J R Coll Physicians Edinb; 2020 Jun; 50(2):114-117. PubMed ID: 32568279 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Salloum IM; Cornelius JR; Daley DC; Kirisci L; Himmelhoch JM; Thase ME Arch Gen Psychiatry; 2005 Jan; 62(1):37-45. PubMed ID: 15630071 [TBL] [Abstract][Full Text] [Related]
20. [Prescribing valproate to girls and women of childbearing age in Germany : Analysis of trends based on claims data]. Wentzell N; Haug U; Schink T; Engel S; Liebentraut J; Linder R; Onken M; Schaefer C; Dathe K Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Aug; 61(8):1022-1029. PubMed ID: 29922910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]